Table 3.
Predictors for the development of pancreatic cancer in univariable analysis
| Variables | PDAC (n=10) |
No PDAC (n=356) |
P value |
| Patient characteristics | |||
| Age, median (IQR) | 57 (16) | 54 (13) | 0.75 |
| Mutation carrier, n (%) | 10 (100) | 155 (44) | <0.001 |
| History of non-pancreatic malignancy, n (%) | 5 (50) | 100 (28) | 0.16 |
| History of diabetes mellitus, n (%) | 1 (10) | 15 (4) | 0.36 |
| Smoking, n (%) | 3 (30) | 45 (13) | 0.37 |
| Family characteristics | |||
| Total number of blood relatives with PDAC, median (IQR) | 2 (3) | 2 (1) | 0.83 |
| Blood relative with PDAC<50 years of age, n (%) | 3 (30) | 120 (34) | >0.99 |
| Pancreatic abnormalities on imaging | |||
| Solid lesion, n (%) | 7 (70) | 14 (4) | <0.001 |
| Indeterminate lesion*, n (%) | 1 (10) | 33 (9) | >0.99 |
| Cystic lesion, n (%) | 5 (50) | 188 (53) | >0.99 |
| Cystic lesion with solid component or mural nodule, n (%) | 2 (20) | 3 (1) | 0.006 |
| Cystic lesion with growth speed>5 mm/year, n (%) | 3 (30) | 22 (6) | 0.03 |
| Main pancreatic duct 5–9 mm (with or without focal lesion), n (%) | 4 (40) | 17 (5) | 0.001 |
Patient and family characteristics were assessed at baseline, pancreatic abnormalities scored if present at any visit.
*Hypoechoic or hypointense lesions of unknown significance that could not with certainty be classified as solid or cystic at diagnosis.
PDAC, pancreatic ductal adenocarcinoma.